New therapeutic options are needed and an active area of research is the CD95/Fas receptor and its ligand CD95L/FasL, which are involved in tumor progression, invasiveness, the development of resistance to radiotherapy and immune therapy and survival of cancer stem cells after therapy, which is associated with relapse2. The gene discussed is FASLG; the disease is cancer.